FDA Orange Book · active-ingredient family
Sodium bicarbonate
Sodium bicarbonate is approved as 1 brand and 15 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:SODIUM BICARBONATE IN PLASTIC CONTAINER · NDA 019443
1
Brand (NDA)
15
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · solution
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| SODIUM BICARBONATE IN PLASTIC CONTAINERRLD×2 | ABBOTT | NDA 019443 | — | Jun 03, 1986 |
Generic (ANDA) products (15)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| SODIUM BICARBONATE×3 | ASPIRO | ANDA 220788 | AP | Apr 15, 2026 | |
| SODIUM BICARBONATE | AMNEAL | ANDA 217523 | AP | Jan 13, 2026 | |
| SODIUM BICARBONATE×2 | FRESENIUS KABI USA | ANDA 206688 | AP | Aug 25, 2025 | |
| SODIUM BICARBONATE | ANTHEA PHARMA | ANDA 219701 | AP | Jun 26, 2025 | |
| SODIUM BICARBONATE | LONG GROVE PHARMS | ANDA 216042 | AP | Feb 27, 2024 | |
| SODIUM BICARBONATE | STERISCIENCE | ANDA 217594 | AP | Jun 28, 2023 | |
| SODIUM BICARBONATE | OMNIVIUM PHARMS | ANDA 216364 | AP | Jun 15, 2023 | |
| SODIUM BICARBONATE×4 | EXELA PHARMA | ANDA 211091 | AP | Jun 20, 2019 | |
| SODIUM BICARBONATE | HOSPIRA | ANDA 202432 | AP | Sep 26, 2017 | |
| SODIUM BICARBONATE | INTL MEDICATION SYS | ANDA 203449 | AP | Sep 19, 2017 | |
| SODIUM BICARBONATE | HOSPIRA | ANDA 202679 | AP | Mar 07, 2017 | |
| SODIUM BICARBONATE | HOSPIRA | ANDA 202495 | AP | Mar 06, 2017 | |
| SODIUM BICARBONATE×2 | HOSPIRA | ANDA 202494 | AP | Mar 06, 2017 | |
| SODIUM BICARBONATE | HOSPIRA | ANDA 202981 | AP | Mar 04, 2016 | |
| SODIUM BICARBONATE×2 | HOSPIRA | ANDA 077394 | — | Nov 09, 2005 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Sodium bicarbonate — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

